Compare Amylx Pharmaceuticals Inc (AMLX) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Amylx Pharmaceuticals Inc trades at $23.68 (market cap $2.64B), while Synchrony Financial trades at $79.16 (market cap $25.53B). The key difference: Synchrony Financial is far larger — about 9.7× Amylx Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.73% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SYF | |
|---|---|---|
Market Cap | $2.64B | $25.53B |
Sector | Health | Financials |
52-Week High | $24.19 | $88.47 |
52-Week Low | $7.82 | $63.78 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Synchrony Financial (SYF) trades at $78.78, up 0.75% today, with strong technical momentum as the stock tests resistance near $79. Recent earnings beats, including Q2 2026 EPS of $2.59 versus $2.14 expected, highlight robust fundamentals. The company maintains a net income margin of 23.4% and a low P/E of 8.05, signaling potential undervaluation. A new partnership with Stripe for CareCredit expansion and a $0.34 dividend reinforce positive business developments.
SYF presents a compelling investment case with analyst consensus bullish—62.5% buy ratings and an $86.33 price target imply ~10% upside. Risks include rising interest expenses of $4.14B and a projected negative net cash flow in 2026. Aggressive share buybacks and stable credit trends support upside, but macroeconomic pressures on consumer spending warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
